Torrent Pharma to buy Unichem Labs' India business for $558 mln

Image
Reuters
Last Updated : Nov 03 2017 | 6:07 PM IST

REUTERS - Torrent Pharmaceuticals said on Friday it would buy more than 120 brands from Unichem Laboratories in India and Nepal, and its manufacturing plant at Sikkim.

The 36 billion rupee ($558 million) deal will be funded by internal accruals and bank borrowing, the Ahmedabad, Gujarat-based drugmaker said in a stock exchange filing.

The acquisition is on a going concern basis and is expected to deliver cost and revenue synergies in Torrent's branded drugs business in India, the company added.

The transaction will strengthen Torrent's position in cardiology, diabetology, gastro-intestinals and central nervous systems therapies, Torrent chairman Samir Mehta said.

The deal includes the purchase of the brand Unienzyme, allowing Torrent to enter the over-the-counter drugs market, as well as brands including Losar, Ampoxin and Telsar.

Under the acquisition, which is expected to close by the end of 2017, more than 3,000 Unichem employees will join Torrent.

($1 = 64.5450 rupees)

(Reporting by Jessica Kuruthukulangara in Bengaluru; Editing by David Goodman and Alexander Smith)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 03 2017 | 5:57 PM IST

Next Story